Effect of XXXX on resting state default mode network activity in @entity195 .

@entity1 @entity3393 @entity195
BACKGROUND: @entity3393 is an approved symptomatic treatment for moderate to severe @entity195 that reduces the excitotoxic effects of hyperactive glutamatergic transmission. However, the exact mechanism of the effect of @entity3393 in @entity195 @entity1 is poorly understood. Importantly, the default mode network (DMN), which plays a key role in attention, is hypoactive in @entity195 and is under glutamatergic control. OBJECTIVE: To assess the effect of @entity3393 on the activity of the DMN in moderate to severe @entity195 . METHODS: Functional magnetic resonance imaging (MRI) data from 15 @entity1 with moderate to severe @entity195 , seven treated with @entity3393 (mean    SD age 77    8 years, mean    SD Mini-Mental State Examination [MMSE] score 16    5) and eight with placebo (mean    SD age 76    6 years, mean    SD MMSE score 13    1), were acquired at baseline (T0) and after 6 months of treatment (T6). Resting state components were extracted after spatial normalization in individual @entity1 with independent component analysis. The consistency of the components was assessed using ICASSO and the DMN was recognized through spatial correlation with a pre-defined template. Voxel-based statistical analyses were performed to study the change in DMN activity from T0 to T6 in the two groups. RESULTS: At T0, the two groups showed similar DMN activity except in the precuneus and cuneus, where the @entity1 who started treatment with @entity3393 had slightly greater activity (p < 0.05 corrected for familywise error [FWE]). The prospective comparison between T0 and T6 in the treated @entity1 showed increased DMN activation mapping in the precuneus (p < 0.05, FWE corrected), while the prospective comparison in the untreated @entity1 did not show significant changes. The treatment * time interaction term was significant at p < 0.05, FWE corrected. CONCLUSIONS: The results suggest a positive effect of @entity3393 treatment in @entity1 with moderate to severe @entity195 , resulting in an increased resting DMN activity in the precuneus region over 6 months. Future studies confirming the present findings are required to further demonstrate the beneficial effects of @entity3393 on the DMN in @entity195 .
